• ARCA Cy5 EGFP mRNA (5-moUTP) Guide

  2026-09-16

  Learn how ARCA Cy5 EGFP mRNA (5-moUTP), SKU R1009, separates mRNA uptake from translation in mammalian-cell viability and delivery studies. This scenario-based guide covers experimental design, handling, data interpretation, and practical vendor selection using product specifications and a peer-reviewed mRNA LNP workflow.

• Cannabidiol in Orofacial Pain: Mechanisms and Implications

  2026-09-16

  This 2026 study shows that cannabidiol reduces inflammatory pain across sensory, affective, and cognitive domains through distinct peripheral, central, endocannabinoid, and serotonergic mechanisms. Its design provides a useful framework for connecting pain behavior with molecular and circuit-level measurements while highlighting where receptor-specific causal tests remain necessary.

• E-64d Workflows for Calpain and Cell-Death Studies

  2026-09-15

  E-64d is a cell-permeable, irreversible cysteine protease inhibitor suited to separating calpain- and cathepsin-dependent phenotypes from broader cell-death effects. This workflow combines careful dose preparation with time-resolved measurements inspired by MEDUSA, improving interpretation in platelet, apoptosis, neuroprotection, and cancer research.

• Cell Counting Kit-8 (CCK-8) Lab Guide

  2026-09-15

  This scenario-driven guide explains how Cell Counting Kit-8 (CCK-8), SKU K1018, can address common variability in cell viability, proliferation, and cytotoxicity workflows. It connects assay chemistry with experimental controls, protocol optimization, interpretation, and practical product selection for biomedical research.

• REC8 Stabilizes MAVS and STING in Antiviral Immunity

  2026-09-14

  Chen and colleagues identify REC8 as an unexpected positive regulator of antiviral innate immunity. Their findings connect SUMO-dependent REC8 relocalization with protection of MAVS and STING from RNF5-driven K48-linked ubiquitination, clarifying how adaptor stability can reinforce type I interferon induction.

• EdU Flow Cytometry Assay Kits (Cy5)

  2026-09-14

  EdU Flow Cytometry Assay Kits (Cy5) provide a practical way to measure DNA synthesis during S-phase using EdU incorporation and Cy5 click-chemistry detection. This dossier-based workflow is suitable for research applications such as cell proliferation, genotoxicity, and pharmacodynamic studies, but it should not be used as a standalone clinical diagnostic or in vivo labeling method.

• Mcl-1 Epigenetic Targeting in Glioblastoma

  2026-09-13

  The reference study identifies a super-enhancer at the MCL1 locus as a determinant of apoptotic resistance in glioblastoma and shows that its disruption sensitizes tumor models to BCL-2/BCL-xL inhibition. By combining ChIP-seq, THZ1 treatment, BH3 mimetics, mitochondrial apoptosis readouts, and patient-derived xenografts, the work provides a mechanistic framework for co-targeting transcriptional regulation and anti-apoptotic signaling.

• Alfuzosin HCl: Bench-to-Formulation Workflows

  2026-09-12

  Build reproducible Alfuzosin HCl assays that connect α1-receptor pharmacology with dissolution, gastroretention, and analytical quality control. This workflow translates the reference study’s low-density sponge platform into practical formulation screens, release tests, and troubleshooting decisions.

• 2'3'-cGAMP: Designing Better STING Assays

  2026-09-11

  2'3'-cGAMP (sodium salt) is a precise tool for dissecting cGAS-STING signaling pathway activity. This guide explains how ligand chemistry, endothelial signaling, and assay architecture shape interpretable immunotherapy research results.

• Canine Mammary Tumor Models Reveal PI3K/Akt Vulnerability

  2026-09-11

  Park and colleagues established canine mammary gland tumor cell lines that reproduce proliferative, anchorage-independent, and epithelial–mesenchymal transition-associated features of canine tumors. Their finding that PI3K inhibition with BYL719 suppresses cell growth positions these models as useful platforms for studying tumor biology and evaluating pathway-directed therapies.

• Oridonin and Inflammation in Esophageal Cancer

  2026-09-10

  Peng et al. show that oridonin improves pathological and inflammatory features in a 4-nitroquinoline N-oxide mouse model of esophageal cancer while suppressing the TLR4/NF-κB/NLRP3 inflammasome axis. The study is valuable for connecting tissue pathology, systemic inflammatory indices, and molecular measurements, although its preclinical design does not establish clinical efficacy or direct pathway causality.

• Gamma-linolenic Acid (GLA) Research Workflows

  2026-09-10

  Build reproducible GLA studies around LTB4 receptor binding, inflammatory-cell responses, oxidative protection, and apoptosis rather than relying on a single endpoint. This practical guide also shows how hospital resistance-surveillance methods can sharpen translational assay design without overstating GLA as an antimicrobial.

• CARMIL Membrane Binding and Actin Assembly

  2026-09-09

  A recent preprint shows that the CARMIL membrane-binding domain is an active regulator of capping protein, not merely a membrane-targeting tether. Its membrane association recruits capping protein and supports Arp2/3-dependent actin assembly, while subsequent release of the domain may promote uncapping and soluble capping-protein activity.

• AR Heterogeneity Shapes Castration and Enzalutamide Response

  2026-09-09

  Li and colleagues show that androgen receptor heterogeneity is a functional determinant of castration-resistant prostate cancer behavior and treatment response, rather than merely a descriptive staining pattern. By combining patient tumor analysis, xenografts, isogenic AR-manipulated LNCaP models, transcriptomics, and combination therapy experiments, the study identifies distinct AR-dependent and AR-low disease states and supports BCL-2 as a context-sensitive therapeutic target.

• nor-Binaltorphimine dihydrochloride in OIH Assays

  2026-09-08

  Use nor-Binaltorphimine dihydrochloride to test whether κ-opioid receptor signaling causally contributes to opioid-induced mechanical hypersensitivity, tolerance, and circuit-level pain responses. This workflow connects controlled antagonist assays with receptor pharmacology, spinal pathway experiments, and reproducible behavioral readouts.

8520 records 1/568 page Next 12345 下5页 Last page